PulmOne News
4 articles
growth-positive
Portable lung tests help patients breathe easier - Sponsored Content The Times of Israel
PulmOne, an Israeli startup, has developed MiniBox+, a compact device that allows pulmonary tests to be performed in clinics everywhere, reducing costs and speeding up diagnosis of lung diseases. The device, which has received FDA clearance, uses patented algorithms, machine-based learning, and an internal gasless measurement system to replace the traditional large, cumbersome equipment. PulmOne has signed agreements with a top US healthcare company and a leading medical technology distributor in China, and its revenues have more than doubled from 2020 to 2021. The company is currently raising funds on the OurCrowd platform.
CustomersPartnersInvestmentExpand
growth-positive
קרן רגנאר תשקיע 6.5 מיליון שקל בחברת המכשור הרפואי פאלם וואן כלכליסט
Regenar Fund is investing 6.5 million shekels in PalmOne, a company that develops and markets advanced medical equipment for lung function tests. PalmOne was aiming for an IPO at a value of $120 million, but business losses led to indications that it would not be able to raise the amount and the IPO was postponed. Instead, the company raised funds from Regenar at a value to be determined in the future. PalmOne has approval to market its products in the European Union since 2013, and from the American FDA since 2014.
Investment
growth-positive
פאלם וואן רוצה להנפיק בתל אביב לפי שווי של 120 מיליון דולר
Israeli medical equipment company Pulm One has received FDA and European Union approval to market its flagship device for lung function testing. The company has begun sales, including to medical centers in the US. The medical equipment market for lungs and breathing has seen increased demand due to the coronavirus, growing by 261% between 2019 and 2020. Pulm One is interested in issuing on the Tel Aviv Stock Exchange at a value of $120 million (420 million shekels).
Public Trading
growth-positive
PulmOne Now Offering FeNO by NIOX® with Its MiniBox+™ Complete Pulmonary Function Testing System
PulmOne USA Inc. has partnered with Circassia Pharmaceuticals to integrate the NIOX VERO fractional exhaled nitric oxide (FeNO) airway inflammation measurement system into PulmOnes MiniBox+. The integrated system will be offered to existing and new customers. The MiniBox+ is used by specialists and primary care physicians for complete Pulmonary Function Testing (PFT) of their patients. The integration of the NIOX VERO asthma management system expands the testing capabilities of the MiniBox+, enabling physicians to detect and treat a wider range of respiratory disorders.
PartnersCustomers
